Manning & Napier Group's DGX Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 17,296 shares of Quest Diagnostics Incorporated (DGX) worth $3.41 M, representing 0.05% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2021, adding 28,511 shares. Largest reduction occurred in Q2 2015, reducing 195,674 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -1,167 | Reduce 6.32% | 17,296 | $197.16 |
| Q4 2025 | -1,793 | Reduce 8.85% | 18,463 | $175.49 |
| Q3 2025 | -11,341 | Reduce 35.89% | 20,256 | $190.58 |
| Q2 2025 | +8,720 | Add 38.12% | 31,597 | $179.63 |
| Q1 2025 | -2,823 | Reduce 10.98% | 22,877 | $169.20 |
| Q4 2024 | -2,789 | Reduce 9.79% | 25,700 | $150.86 |
| Q3 2024 | -9,982 | Reduce 25.95% | 28,489 | $155.25 |
| Q2 2024 | +1,410 | Add 3.80% | 38,471 | $136.88 |
| Q1 2024 | -3,170 | Reduce 7.88% | 37,061 | $133.08 |
| Q4 2023 | -7,923 | Reduce 16.45% | 40,231 | $137.88 |
| Q3 2023 | -1,510 | Reduce 3.04% | 48,154 | $121.86 |
| Q2 2023 | +4,863 | Add 10.85% | 49,664 | $140.56 |
| Q1 2023 | -110 | Reduce 0.24% | 44,801 | $141.48 |
| Q4 2022 | -973 | Reduce 2.12% | 44,911 | $156.44 |
| Q3 2022 | -686 | Reduce 1.47% | 45,884 | $122.68 |
| Q2 2022 | -26,447 | Reduce 36.22% | 46,570 | $132.96 |
| Q1 2022 | -2,705 | Reduce 3.57% | 73,017 | $136.84 |
| Q4 2021 | -4,691 | Reduce 5.83% | 75,722 | $173.00 |
| Q3 2021 | -1,112 | Reduce 1.36% | 80,413 | $145.30 |
| Q2 2021 | +28,511 | Add 53.78% | 81,525 | $131.96 |
| Q1 2021 | +703 | Add 1.34% | 53,014 | $128.32 |
| Q4 2020 | +3,643 | Add 7.49% | 52,311 | $119.15 |
| Q3 2020 | +101 | Add 0.21% | 48,668 | $114.47 |
| Q2 2020 | -4,596 | Reduce 8.65% | 48,567 | $113.95 |
| Q1 2020 | +8,303 | Add 18.51% | 53,163 | $80.28 |
| Q4 2019 | +1,647 | Add 3.81% | 44,860 | $106.75 |
| Q3 2019 | -79 | Reduce 0.18% | 43,213 | $107.00 |
| Q2 2019 | +10,067 | Add 30.30% | 43,292 | $101.80 |
| Q1 2019 | +10,891 | Add 48.76% | 33,225 | $89.90 |
| Q4 2018 | +2,415 | Add 12.12% | 22,334 | $83.24 |
| Q3 2018 | +3,099 | Add 18.42% | 19,919 | $107.89 |
| Q2 2018 | +16,820 | New Buy | 16,820 | $109.87 |
| Q2 2017 | -7,625 | Sold Out | 0 | $0.00 |
| Q4 2016 | +7,625 | New Buy | 7,625 | $91.80 |
| Q2 2015 | -195,674 | Sold Out | 0 | $0.00 |
| Q3 2014 | +2,250 | Add 1.16% | 195,674 | $60.67 |
| Q2 2014 | +1,934 | Add 1.01% | 193,424 | $58.68 |
| Q1 2014 | +191,490 | New Buy | 191,490 | $57.91 |
Manning & Napier Group's Quest Diagnostics Incorporated Investment FAQs
Manning & Napier Group first purchased Quest Diagnostics Incorporated (DGX) in Q1 2014, acquiring 191,490 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Quest Diagnostics Incorporated (DGX) for 41 quarters since Q1 2014.
Manning & Napier Group's largest addition to Quest Diagnostics Incorporated (DGX) was in Q1 2014, adding 191,490 shares worth $11.09 M.
According to the latest 13F filing for Q1 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 17,296 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $3.41 M.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.05% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Quest Diagnostics Incorporated (DGX) was 195,674 shares, as reported at the end of Q3 2014.